Pengaruh Penyakit Penyerta terhadap Toksisitas Obat Metamizole
DOI:
https://doi.org/10.20527/jps.v10i1.13920Keywords:
Co-morbidities, Metamizole, Toxicity, Drug Interactions, Drug Side EffectAbstract
Metamizole merupakan obat yang memiliki efek analgesik, antipiretik, dan spasmolitik. Metamizole diketahui memiliki toksisitas yang dipengaruhi oleh penyakit penyerta, dosis dan interaksi obat. Hal ini yang menjadi salah satu latar belakang bagi peneliti untuk membahas lebih lanjut terkait pengaruh penyakit penyerta terhadap toksisitas metamizole. Penelitian ini bertujuan untuk mengkaji pengaruh penyakit penyerta terhadap toksisitas obat metamizole. Desain penelitian yang digunakan adalah literature review dan data yang digunakan berasal dari Google Schoolar, PubMed, dan Science Direct. Hasil dari review sepuluh jurnal menunjukkan bahwa adanya pengaruh penyakit penyerta seperti kardiovaskular, autoimun, infeksi virus, acute liver injury, kanker dan asma terhadap toksisitas obat metamizole. Pengaruh ini sering kali diperberat oleh interaksi obat seperti obat aspirin, antibiotik, antikonvulsan, dan cDMARD (methotrexate). Kesimpulan review ini adalah adanya pengaruh penyakit penyerta terhadap toksisitas obat metamizole. Penyakit penyerta tersebut antara lain adalah kardiovaskular yang dapat menyebabkan MACCE (P<0,001), autoimun yang dapat meningkatkan resiko agranulositosis dengan OR 2,28 (CI 95%: 1,294,04), infeksi virus, acute liver injury, kanker dan asma. Kata Kunci: Penyakit Penyerta, Toksisitas, Metamizole, Interaksi Obat, Efek Samping Obat Metamizole is a drug that has analgesic, antipyretic, and spasmolytic effects. Metamizole is known to have a toxicity that is influenced by comorbidities, dosage, and drug interactions. This is one of the backgrounds for researchers to discuss further regarding the effect of co-morbidities on metamizole toxicity. This study aims to examine the effect of comorbidities on the toxicity of the metamizole. The research design used was a literature review and the data used came from Google Schoolar, PubMed, and Science Direct. The results of a review of ten journals showed that there was an influence of comorbidities such as cardiovascular, autoimmune, viral infections, acute liver injury, cancer, and asthma on the toxicity of the metamizole. This effect is often exacerbated by drug interactions such as aspirin, antibiotics, anticonvulsants, and cDMARD (methotrexate). The conclusion of this study is that there is an effect of comorbidities on the toxicity of the metamizole. These comorbidities include cardiovascular disease that can cause MACCE (P < 0.001), autoimmune which can increase the risk of agranulocytosis with an OR of 2.28 (95% CI: 1.29 4.04), viral infections, acute liver injury, cancer and asthma.References
Andrès, E., Villalba, N. L., Zulfiqar, A. A., Serraj, K., Mourot-Cottet, R., & Gottenberg, J. E. (2019). State of art of idiosyncratic drug-induced neutropenia or agranulocytosis, with a focus on biotherapies. Journal of Clinical Medicine, 8(9). https://doi.org/10.3390/jcm8091351
Bailey, C. J., Drummond, M. J., & Ward, P. R. (2019). Food literacy programmes in secondary schools: A systematic literature review and narrative synthesis of quantitative and qualitative evidence. Public Health Nutrition, 22(15), 2891–2913. https://doi.org/10.1017/S1368980019001666
Blaser, L., Hassna, H., Hofmann, S., Holbro, A., Haschke, M., Rätz Bravo, A., Zeller, A., Krähenbühl, S., & Taegtmeyer, A. (2017). Leucopenia associated with metamizole: a case-control study. Swiss Medical Weekly, 147(May), w14438. https://doi.org/10.4414/smw.2017.14438
Dannenberg, L., Petzold, T., Achilles, A., Naguib, D., Zako, S., Helten, C., M‘Pembele, R., Mourikis, P., Podsvyadek, Y., Grandoch, M., Levkau, B., Zeus, T., Kelm, M., Hohlfeld, T., & Polzin, A. (2019). Dose reduction, oral application, and order of intake to preserve aspirin antiplatelet effects in dipyrone co-medicated chronic artery disease patients. European Journal of Clinical Pharmacology, 75(1), 13–20. https://doi.org/10.1007/s00228-018-2560-z
Dewi, C. C. (2019). Tinjauan atas Stevens-Johnson Syndrome dan Toxic Epidermal Necrolysis. Cermin Dunia Kedokteran, 46(7), 55–59. http://www.cdkjournal.com/index.php/CDK/article/view/457
Eurupean Medicines Agency. (2018). Assessment Report: Metamizole-Containing Medicinal Products. https://www.ema.europa.eu/en/documents/referral/metamizole-article-31-referral-chmp-assessment-report_en.pdf (diakses 18 Mei 2021)
Ghafar, N. H. Universiti Kuala Lumpur, Malaysian, (2015). Systematic Literature Review : Mapping the Topology of a Decade of of the Talent Management Research. South East Asia Journal of Contemporary Business, Economics and Law, Vol. 6, Issue 2 (Apr.) ISSN 2289-1560, 6(2).
Hoffmann, F., Bantel, C., & Jobski, K. (2020). Agranulocytosis attributed to metamizole: An analysis of spontaneous reports in EudraVigilance 1985-2017. Basic and Clinical Pharmacology and Toxicology, 126(2), 116–125. https://doi.org/10.1111/bcpt.13310
Lerman, T. T., Sagi, M., Shafir, Y., Sheena, L., Cohen, E., Goldberg, E., & Krause, I. (2021). A possible increased risk of metamizole-associated neutropenia among COVID-19 patients. British Journal of Clinical Pharmacology, 87(7), 2902–2906. https://doi.org/10.1111/bcp.14703
Lobo, S. (2020). Is there enough focus on lipophilicity in drug discovery? Expert Opinion on Drug Discovery, 15(3), 261–263. https://doi.org/10.1080/17460441.2020.1691995
Lutz, M. (2019). Metamizole (Dipyrone) and the Liver: A Review of the Literature. Journal of Clinical Pharmacology, 59(11), 1433–1442. https://doi.org/10.1002/jcph.1512
Miljković, M., RanÄić, N., Simić, R., Stamenković, D., & Dragojević-Simić, V. (2018). Metamizole: Current status of the safety and efficacy. Hospital Pharmacology - International Multidisciplinary Journal, 5(3), 694–704. https://doi.org/10.5937/hpimj1803694m
Munir, F., Javaid, H. W., Rana, M. B. M., & Shaukat, F. (2022). Ceftriaxone-Induced Reversible Agranulocytosis: A Case Report and Review of Drug-Induced Agranulocytosis. Cureus, 14(3), 10–14. https://doi.org/10.7759/cureus.23226
Nikolova, I., Tencheva, J., Voinikov, J., Petkova, V., Benbasat, N., & Danchev, N. (2012). Metamizole: A review profile of a well-known “forgotten†drug. Part I: Pharmaceutical and nonclinical profile. Biotechnology and Biotechnological Equipment, 26(6), 3329–3337. https://doi.org/10.5504/bbEq.2012.0089
Nurfita, Arifian, H., & Fadraersada, J. (2018). Analisis Biaya Minimal dan Efektivitas Biaya Penggunaan Analgesik Pada Pasien Bedah Sesar di Salah Satu Rumah Sakit Samarinda. Proceeding of Mulawarman Pharmaceuticals Conferences, 8(November 2018), 75–80. https://doi.org/10.25026/mpc.v8i1.306
Ott, H. (2011). Hypersensitivity Reactions to Drugs. Harper’s Textbook of Pediatric Dermatology: Third Edition, 2, 1–14. https://doi.org/10.1002/9781444345384.ch183
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., & Moher, D. (2021). Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. Journal of Clinical Epidemiology, 134, 103–112. https://doi.org/10.1016/j.jclinepi.2021.02.003
Pflugbeil, S., Böckl, K., Pongratz, R., Leitner, M., Graninger, W., & Ortner, A. (2020). Drug interactions in the treatment of rheumatoid arthritis and psoriatic arthritis. Rheumatology International, 40(4), 511–521. https://doi.org/10.1007/s00296-020-04526-3
Polzin, A., Dannenberg, L., Helten, C., Pöhl, M., Metzen, D., Mourikis, P., Dücker, C., Marschall, U., L’hoest, H., Hennig, B., Zako, S., Trojovsky, K., Petzold, T., Jung, C., Levkau, B., Zeus, T., Schrör, K., Hohlfeld, T., & Kelm, M. (2021). Excess mortality in aspirin and dipyrone (Metamizole) co-medicated in patients with cardiovascular disease: A nationwide study. Journal of the American Heart Association, 10(22), 1–11. https://doi.org/10.1161/JAHA.121.022299
RodrÃguez-MartÃn, S., MartÃn-Merino, E., Lerma, V., RodrÃguez-Miguel, A., González, O., González-Herrada, C., RamÃrez, E., Bellón, T., & de Abajo, F. J. (2018). Active surveillance of severe cutaneous adverse reactions: A case-population approach using a registry and a health care database. Pharmacoepidemiology and Drug Safety, 27(9), 1042–1050. https://doi.org/10.1002/pds.4622
Rudin, D., Roos, N. J., Duthaler, U., & Krähenbühl, S. (2019). Toxicity of metamizole on differentiating HL60 cells and human neutrophil granulocytes. Toxicology, 426(May), 152254. https://doi.org/10.1016/j.tox.2019.152254
Santos-Gallego, C. G., & Badimon, J. (2021). Overview of Aspirin and Platelet Biology. American Journal of Cardiology, 144, S2–S9. https://doi.org/10.1016/j.amjcard.2020.12.018
Sierocinski, E., Angelow, A., Mainz, A., Walker, J., & Chenot, J. F. (2021). Patient safety in the treatment of rheumatic diseases: Laboratory monitoring in methotrexate treatment. Zeitschrift Fur Rheumatologie, 80(5), 418–424. https://doi.org/10.1007/s00393-021-00976-7
Sulistiani, N. D., Ardana, M., & Fadraersada, J. (2018). Studi Penggunaan Analgesik dan Antibiotik pada Pasien Fraktur. Proceeding of Mulawarman Pharmaceuticals Conferences, 8(November), 89–96. https://doi.org/10.25026/mpc.v8i1.308
Theken, K. N., Lee, C. R., Gong, L., Caudle, K. E., Formea, C. M., Gaedigk, A., Klein, T. E., Agúndez, J. A. G., & Grosser, T. (2020). Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clinical Pharmacology and Therapeutics, 108(2), 191–200. https://doi.org/10.1002/cpt.1830
Weber, S., Benesic, A., et al. (2021). Liver Injury Associated with Metamizole Exposure: Features of an Underestimated Adverse Event. Drug Safety, 44(6), 669–680. https://doi.org/10.1007/s40264-021-01049-z
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
.jpg)
